[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Olistic Research Labs S.L.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100630160","efficacy-and-safety-of-a-drinkable-nutraceutical-for-hair-loss-in-patients-using-glp-1gip-receptor-agonists-100630160",false,"NCT07484061","Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1\u002FGIP Receptor Agonists","Evaluation of the Efficacy and Safety of a Drinkable Nutraceutical in Improving Hair Loss in Patients Treated With GLP-1\u002FGIP Receptor Agonists: a Double-blind, 1:1 Randomized, Placebo-controlled Study.","Inclusion Criteria:\n\n* Female gender.\n* Age \\>35 years.\n* Initiation of treatment with a GLP-1\u002FGIP agonist, or treatment duration \\\u003C 3 months, as per routine clinical practice in the endocrinology clinic.\n* Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.\n* Additional criteria to be included by the client.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.\n* Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.\n* Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).\n* Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.\n* Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.\n* Women who have used anti-hair loss products within the last 3 months.\n* Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).\n* Women who have undergone hair transplantation within the 18 months prior to study initiation.\n* Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.\n* Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.\n* Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.\n* Additional exclusion criteria to be specified by the sponsor.\n* Any condition that, in the investigator's opinion, makes participation in the study inappropriate.","FEMALE","35 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1\u002FGIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.",[26],"Telogen Effluvium","RECRUITING","2026-03-19",{"date":30,"type":31},"2026-03-23","ACTUAL",{"date":33,"type":31},"2026-03-16",{"date":35,"type":20},"2026-10-31",{"name":37,"class":38},"Olistic Research Labs S.L.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100619632","clinical-evaluation-of-a-nutraceutical-supplement-for-hair-growth-hair-loss-and-skin-improvement-in-human-volunteers-100619632","NCT07347145","Clinical Evaluation of a Nutraceutical Supplement for Hair Growth, Hair Loss and Skin Improvement in Human Volunteers","Clinical Evaluation of Hair Loss and Hair Growth Human Volunteers Following a Double-blind, Placebo-controlled, 2:1 Randomized Trial of 'Olistic Next Women'","Inclusion Criteria:\n\n* Female subjects with female pattern hair loss\n* 45-65 years\n* Signed informed consent\n* The study participant is in good general condition for her age and does not currently have any active diseases that, in the opinion of the investigator, justify exclusion from the study.\n\nExclusion Criteria:\n\n* Known or documented intolerance\u002Fallergy to any of the ingredients of the study product\n* Chronic wounds, erosions, pre-existing infected skin or inflammation in the study area\n* Suspected non-compliance\n* Late onset acne\n* Hirsutism\n* Any systemic immunosuppressant given within the 12 months prior to the study (e.g. systemic Prednisolone in high doses, Azathioprine, Metothrexate etc.)\n* Locally (in the study area) applied products\u002Fmedicaments which in the opinion of the investigator could lead to an influence of the study results (e.g. topical minoxidil, caffeine etc.)\n* Systemically administered products and medicaments which in the opinion of the investigator could lead to an influence of the study results (e.g. hormone-influencing medicaments, medicaments which frequently lead to hypertrichosis or hair loss etc.)\n* Subjects receiving stable hormone replacement therapy (HRT) for \\\u003C6 months prior to screening will be excluded.\n* Subjects who follow an exclusively or mainly vegan diet\n* Known or documented Gluten intolerance\n* Lactose intolerance\n* Hyperthyroidism\n* Subjects with hypothyroidism with non-stable thyroid-stimulating hormone (TSH) levels will be excluded.\n* Other diseases of the scalp which in the opinion of the investigator could lead to an influence of the study results (e.g. Lichen planus, Psoriasis capitis, scarring alopecia etc.)\n* Participation in a clinical trial\u002Fstudy\n* Participation in a clinical trial\u002Fstudy within the last 30 days\n* Deviations from the norm in the following laboratory values in the blood test of the screening visit: zinc, ferritin, selenium, folic acid, vitamin B12, TSH, and CRP. (Only at Baseline)","45 Years","65 Years",{"count":50,"type":20},60,[23],"The purpose of this clinical trial is to evaluate the efficacy and safety of Olistic Next Women, a nutraceutical supplement, in women experiencing beginning of female pattern hair loss (FPHL).This 6-month, double-blind, placebo-controlled, 2:1 randomized clinical trial investigates whether daily supplementation with Olistic Next Women leads to significant improvements in hair parameters compared to placebo. The study also monitors the tolerability and safety of the product throughout the intervention.",[54],"Early Female Pattern Hair Loss (FPHL)","2026-01-27",{"date":57,"type":31},"2026-01-29",{"date":59,"type":31},"2025-03-03",{"date":61,"type":20},"2026-09",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":48,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":82,"locationsCount":39},"100601500","clinical-evaluation-of-a-nutraceutical-supplement-for-hair-growth-hair-loss-and-skin-improvement-in-human-volunteers-versus-placebo-100601500","NCT07111299","Clinical Evaluation of a Nutraceutical Supplement for Hair Growth, Hair Loss and Skin Improvement in Human Volunteers Versus Placebo","Clinical Evaluation of Hair Loss, Hair Growth, and Skin Improvement in Human Volunteers Following a Double-blind, Placebo-controlled, 1:1 Randomized Trial of 'Olistic Next Women'","Inclusion Criteria:\n\n* Women aged 50-65.\n* Volunteers with initial FPHL. (Images will be sent to a dermatologist for assessment).\n* Commitment not to use systemic, topical, or oral products with an effect similar to that of the product to be evaluated throughout the study period.\n* Do not change the daily routine regarding the use of cosmetic products and eating habits.\n* Commitment to comply with all protocol requirements specified in the subject information sheet.\n* Availability to comply with all study visits.\n\nExclusion Criteria:\n\n* Allergy or reactivity to some of the components of the product, or a product with similar category than tested one.\n* Women who have undergone dermatological treatment for hair loss (PRPs, mesotherapy, etc.) or hair transplant.\n* Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate severe seborrheic dermatitis, eczema, cancer, etc.\n* Women who present alopecia because of a medical illness (hypothyroidism, anemia, lupus, etc.).\n* Relevant cutaneous marks in the experimental areas, which could interfere with the measurements (scars, sunburns, etc.).\n* In-use relevant pharmacological or hormonal treatment (eg. valproic acid, carbamazepine, phenytoin).\n* Women with thyroid alteration (hyper- or hypothyroidism)\n* Women who have previously participated in similar studies or who have used anti-hair loss products in the last 3 months.\n* Women who are being treated with anticoagulants, antifungals, anxiolytics, amphetamines, retinoids, iron, antithyroid, anticonvulsants, beta blockers and\u002For ACE inhibitors, minoxidil, finasteride, etc.\n* Women who started hormonal treatment (oral or topical contraceptives) in the 6 months prior to the start of the study.\n* Women who started taking any drug chronically less than 6 months before the start of the study (they should have a stable situation with the medication over 6 months).\n* Modification of the usual diet: low-calorie diet, Atkins diet, etc.\n* Pregnant, postpartum (6 months) or breastfeeding women, or who intend to get pregnant during the duration of the study.\n* Evidence of systemic diseases (e.g. cardiac disease, psychiatric disease, etc.) or gastrointestinal diseases.\n* Serious conditions or illnesses that, in the opinion of the researcher, may be aggravated by participation in the study or that put the development of the study at risk.\n* Planned hairstyle changes throughout the study\n* Presence of skin diseases or melanomas.\n* Forecast of change of routine or relevant way of life, during the period of study.\n* Other exclusion criteria to be added by the customer.\n* Women who have gone dermatological treatment, that they have introduced minoxidil (oral or topical) at least 6 months prior, and antiandrogens (e.g. finasteride) at least 12 months before the start of the study.","50 Years",{"count":72,"type":20},100,[23],"The purpose of this clinical trial is to evaluate the efficacy and safety of Olistic Next Women, a nutraceutical supplement, in women experiencing beginning of FPHL.\n\nThis 6-month, double-blind, placebo-controlled, 1:1 randomized clinical trial investigates whether daily supplementation with Olistic Next Women leads to significant improvements in hair parameters compared to placebo. The study also monitors the tolerability and safety of the product throughout the intervention.",[54],"2025-12-23",{"date":78,"type":31},"2025-12-30",{"date":80,"type":31},"2025-10-13",{"date":61,"type":20},{"name":37,"class":38},""]